MedPath
Found 438 clinical trials|View Analysis
Sort by:

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1
Not yet recruiting
Conditions
Non-small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small Cell Lung
Non-Small Cell Lung Carcinoma
Non Small Cell Lung Cancer
Non Small Cell Lung Carcinoma
Interventions
First Posted Date
2024-11-19
Last Posted Date
2025-01-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT06694454
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Phase 1
Recruiting
Conditions
Non-Small Cell Lung Cancer
Lung Cancer
NSCLC
NSCLC (Non-small Cell Lung Carcinoma)
EGFR Activating Mutation
EGFR Mutation-Related Tumors
Interventions
Drug: BG-60366
First Posted Date
2024-11-12
Last Posted Date
2024-12-24
Lead Sponsor
BeiGene
Target Recruit Count
93
Registration Number
NCT06685718
Locations
🇺🇸

University of Colorado, Denver, Colorado, United States

🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 16 locations

A Study with NKT3964 for Adults with Advanced/Metastatic Solid Tumors

Phase 1
Recruiting
Conditions
Solid Tumor
Advanced Solid Tumor
Solid Tumor, Adult
Metastatic Tumor
Ovarian Cancer
Ovarian Neoplasms
Ovarian Carcinoma
Metastatic Ovarian Carcinoma
Endometrial Neoplasms
Endometrial Diseases
Interventions
Drug: NKT3964
First Posted Date
2024-09-19
Last Posted Date
2024-11-13
Lead Sponsor
NiKang Therapeutics, Inc.
Target Recruit Count
90
Registration Number
NCT06586957
Locations
🇺🇸

Florida Cancer Specialists & Research Institute, Lake Mary, Florida, United States

🇺🇸

Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States

🇺🇸

John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey, United States

Searching for Predictive Biomarkers of Efficacy in Small Cell Lung Cancer Patients Treated With Chemotherapy-immunotherapy Combination Using Imaging Mass Cytometry (HYPE)

Active, not recruiting
Conditions
Small Cell Lung Carcinoma
First Posted Date
2024-08-19
Last Posted Date
2024-08-19
Lead Sponsor
University Hospital, Brest
Target Recruit Count
20
Registration Number
NCT06558903
Locations
🇫🇷

CHU de Brest, Brest, France

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Phase 1
Recruiting
Conditions
Metastatic Solid Tumor
Advanced Solid Tumor
Non-small Cell Lung Carcinoma
SMARCA4 Mutation
Interventions
Drug: PRT7732
First Posted Date
2024-08-19
Last Posted Date
2024-12-19
Lead Sponsor
Prelude Therapeutics
Target Recruit Count
104
Registration Number
NCT06560645
Locations
🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

🇺🇸

Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York, United States

🇺🇸

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States

and more 6 locations

Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer : EpiTax Study.

Completed
Conditions
Advanced Small Cell Lung Carcinoma
First Posted Date
2024-08-13
Last Posted Date
2024-08-13
Lead Sponsor
University Hospital, Brest
Target Recruit Count
29
Registration Number
NCT06550518
Locations
🇫🇷

CHRU de Brest, Brest, France

🇫🇷

Hôpital de Landerneau, Landerneau, France

🇫🇷

CHIC, Quimper, France

Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer

Phase 2
Recruiting
Conditions
Small Cell Lung Carcinoma
Interventions
Radiation: Radical/Ablative Radiotherapy
Radiation: Palliative Radiotherapy
First Posted Date
2024-07-31
Last Posted Date
2024-07-31
Lead Sponsor
Copernicus Memorial Hospital
Target Recruit Count
165
Registration Number
NCT06529081
Locations
🇵🇱

Copernicus Memorial Hospital in Łódź, Łódź, Łódzkie, Poland

An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy

Phase 2
Not yet recruiting
Conditions
Small Cell Lung Carcinoma
Interventions
Drug: Lurbinectedin
Radiation: Radiation Therapy
First Posted Date
2024-07-15
Last Posted Date
2024-07-15
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
9
Registration Number
NCT06501976

NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

Recruiting
Conditions
Non-squamous Metastatic Non-Small-Cell Lung Carcinoma
First Posted Date
2024-07-10
Last Posted Date
2024-12-18
Lead Sponsor
AstraZeneca
Target Recruit Count
600
Registration Number
NCT06494540
Locations
🇩🇪

Research Site, Wiesbaden, Germany

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Not Applicable
Not yet recruiting
Conditions
ALK+ Non-Small-Cell Lung Carcinoma
Interventions
First Posted Date
2024-07-05
Last Posted Date
2024-11-08
Lead Sponsor
Pfizer
Target Recruit Count
90
Registration Number
NCT06487078
© Copyright 2025. All Rights Reserved by MedPath